Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) Menhycia®

Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) Menhycia®
Product Description

More Serogroup: Men ACWY
Long lasting: immunization memory, High affinity IgG, Mucosal immunity.
Strong Evidence: A 10-year evidence of MenACWY CRM Menhycia® evidence.
Saftey: A 10-year evidence of Men ACWY CRM Menhycia® evidence Safety of CRM 197

Third quadrivalent meningococcal conjugate vaccine in the world and the first in China Suitable for children from 3 months to 3 years (47 months) of age Not contain any preservatives such as phenol or animal-derived components 
CRM197 protein vector technology can obtain stable and safe polysaccharide protein conjugates

Read more Show less

CanSino Biologics Inc.

  • Country/Region:
    China
  • On CPHI since:
    2024
  • Certificates:
    1
  • Employees:
    1000 - 4999
Company types
Biopharmaceutical company
Primary activities
Biopharmaceutical
Technology
View company profile
Categories
more categories Show less
Specifications
  • Selling Points
    Halal Ingredients; Immune Health
  • Model
    Solution for Intramuscular Injection
  • Supplied from
    China
More specifications Fewer specifications
Sales Markets
Show more Show less

CanSino Biologics Inc.

  • Country/Region:
    China
  • On CPHI since:
    2024
  • Certificates:
    1
  • Employees:
    1000 - 4999
Company types
Biopharmaceutical company
Primary activities
Biopharmaceutical
Technology
View company profile

More Products from CanSino Biologics Inc. (2)